Table 2.

HER2-amplified cell lines with increased PI3K/AKT signaling

Cell lineExon 9Exon 20PTENPI3K/AKT signalingT/L
ZR75-30WTWTHighNormalS/S
BT-474WTWTHighNormalS/S
HCC-2218WTWTHighNormalS/S
EFM192AWTWTHighNormalS/S
UACC-812WTWTHighNormalS/S
SKBR3WTWTLowActivatedS/S
UACC-732WTWTHighNormalR/R
JIMT-1WTWTLowActivatedR/R
UACC-893WTH1047RLowActivatedR/R
HCC-1569WTWTLowActivatedR/R
MDA-453WTH1047RLowActivatedR/R
MDA-361E545KWTHighActivatedS/R
HCC-1419WTWTLowActivatedR/S
HCC-202E545KWTHighActivatedD/R
HCC-1954WTH1047RLowActivatedR/S
SUM-190WTH1047RLowActivatedD/S
SUM-225WTWTLowActivatedR/S

NOTE: Median expression level used for high/low cutoff.

Abbreviation: T/L, response to either trastuzumab or lapatinib, respectively.